mFlusiva becomes the first mRNA influenza vaccine approved by the FDA
1. The FLUENT trial demonstrated 26.6% relative vaccine efficacy over a standard-dose comparator in adults 50 and older, clearing the ...
1. The FLUENT trial demonstrated 26.6% relative vaccine efficacy over a standard-dose comparator in adults 50 and older, clearing the ...
1. The FDA's top vaccine advisory committee voted 9-0 on June 18, 2026 to recommend Moderna's mRNA influenza vaccine mFlusiva ...
1. Orforglipron (Foundayo) introduces a new oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken without food or timing ...
1. Sparsentan (Filspari) becomes the first approved treatment specifically for focal segmental glomerulosclerosis. 2. Clinical trial data show meaningful reductions ...
1. In this cross-sectional study, approved label populations were broader overall compared to trial populations for new drugs in the ...
1. This study found that a high proportion of Food and Drug Administration (FDA) drug trials recruit participants from low- ...
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in